Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 3/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21435034 | 0.81 | MAP4K1 (0.32) | RAB9AKMT2AKDM4EPDE9AMAPK1 | |
| SCHEMBL21435020 | 0.81 | CACNA1G (0.36) | PDE9AMAPK1 | |
| SCHEMBL21453308 | 0.78 | CSF1R (0.37) | PDE9ACSF1R | |
| SCHEMBL21435099 | 0.77 | ALDH1A1 (0.35) | ALDH1A1HTTSMN1; SMN2RAB9AKMT2A | |
| SCHEMBL21435084 | 0.73 | BRS3 (0.33) | AOC3CSF1R | |
| SCHEMBL21453769 | 0.73 | PDE1B (0.34) | PDE9AMAPK1CSF1R | |
| SCHEMBL21435216 | 0.73 | KCNH2 (0.33) | ALDH1A1RAB9AKMT2AKDM4E | |
| SCHEMBL21449326 | 0.70 | MAPK1 (0.33) | MAPK1CSF1R | |
| Hydrochloric Acid SCHEMBL21435225 | 0.69 | CSF1R (0.33) | MAPK1CSF1R | |
| SCHEMBL19398933 | 0.68 | PDE1B (0.35) | PDE9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899769-B2 | Imidazopiperazinone inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2019195846-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195846-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308978-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-10 | — | — | US | disclosed |
| US-20190308978-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899769-B2 | Imidazopiperazinone inhibitors of transcription activating proteins | EP300, CREBBP, RBBP4 | ALDH1A1 3128/4885HTT 3389/4885SMN1; SMN2 4037/4885 |
| US-20190308978-A1 | IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP4 | ALDH1A1 3128/4885HTT 3389/4885SMN1; SMN2 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.